Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community

Ultsch B, Damm O, Beutels P, Bilcke J, Brueggenjuergen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, et al. (2016)
PHARMACOECONOMICS 34(3): 227-244.

Download
No fulltext has been uploaded. References only!
Journal Article | Original Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ; ; ; ; ; ;
All
Abstract
Incremental cost-effectiveness and cost-utility analyses [health economic evaluations (HEEs)] of vaccines are routinely considered in decision making on immunization in various industrialized countries. While guidelines advocating more standardization of such HEEs (mainly for curative drugs) exist, several immunization-specific aspects (e.g. indirect effects or discounting approach) are still a subject of debate within the scientific community. The objective of this study was to develop a consensus framework for HEEs of vaccines to support the development of national guidelines in Europe. A systematic literature review was conducted to identify prevailing issues related to HEEs of vaccines. Furthermore, European experts in the field of health economics and immunization decision making were nominated and asked to select relevant aspects for discussion. Based on this, a workshop was held with these experts. Aspects on 'mathematical modelling', 'health economics' and 'decision making' were debated in group-work sessions (GWS) to formulate recommendations and/or-if applicable-to state 'pros' and 'contras'. A total of 13 different aspects were identified for modelling and HEE: model selection, time horizon of models, natural disease history, measures of vaccine-induced protection, duration of vaccine-induced protection, indirect effects apart from herd protection, target population, model calibration and validation, handling uncertainty, discounting, health-related quality of life, cost components, and perspectives. For decision making, there were four aspects regarding the purpose and the integration of HEEs of vaccines in decision making as well as the variation of parameters within uncertainty analyses and the reporting of results from HEEs. For each aspect, background information and an expert consensus were formulated. There was consensus that when HEEs are used to prioritize healthcare funding, this should be done in a consistent way across all interventions, including vaccines. However, proper evaluation of vaccines implies using tools that are not commonly used for therapeutic drugs. Due to the complexity of and uncertainties around vaccination, transparency in the documentation of HEEs and during subsequent decision making is essential.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Ultsch B, Damm O, Beutels P, et al. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PHARMACOECONOMICS. 2016;34(3):227-244.
Ultsch, B., Damm, O., Beutels, P., Bilcke, J., Brueggenjuergen, B., Gerber-Grote, A., Greiner, W., et al. (2016). Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PHARMACOECONOMICS, 34(3), 227-244. doi:10.1007/s40273-015-0335-2
Ultsch, B., Damm, O., Beutels, P., Bilcke, J., Brueggenjuergen, B., Gerber-Grote, A., Greiner, W., Hanquet, G., Hutubessy, R., Jit, M., et al. (2016). Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PHARMACOECONOMICS 34, 227-244.
Ultsch, B., et al., 2016. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PHARMACOECONOMICS, 34(3), p 227-244.
B. Ultsch, et al., “Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community”, PHARMACOECONOMICS, vol. 34, 2016, pp. 227-244.
Ultsch, B., Damm, O., Beutels, P., Bilcke, J., Brueggenjuergen, B., Gerber-Grote, A., Greiner, W., Hanquet, G., Hutubessy, R., Jit, M., Knol, M., von Kries, R., Kuhlmann, A., Levy-Bruhl, D., Perleth, M., Postma, M., Salo, H., Siebert, U., Wasem, J., Wichmann, O.: Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PHARMACOECONOMICS. 34, 227-244 (2016).
Ultsch, Bernhard, Damm, Oliver, Beutels, Philippe, Bilcke, Joke, Brueggenjuergen, Bernd, Gerber-Grote, Andreas, Greiner, Wolfgang, Hanquet, Germaine, Hutubessy, Raymond, Jit, Mark, Knol, Mirjam, von Kries, Ruediger, Kuhlmann, Alexander, Levy-Bruhl, Daniel, Perleth, Matthias, Postma, Maarten, Salo, Heini, Siebert, Uwe, Wasem, Jurgen, and Wichmann, Ole. “Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community”. PHARMACOECONOMICS 34.3 (2016): 227-244.
This data publication is cited in the following publications:
This publication cites the following data publications:

10 Citations in Europe PMC

Data provided by Europe PubMed Central.

Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany - a mathematical modelling study.
Horn J, Damm O, Greiner W, Hengel H, Kretzschmar ME, Siedler A, Ultsch B, Weidemann F, Wichmann O, Karch A, Mikolajczyk RT., BMC Med 16(1), 2018
PMID: 29316913
Evaluating Frameworks That Provide Value Measures for Health Care Interventions.
Mandelblatt JS, Ramsey SD, Lieu TA, Phelps CE., Value Health 20(2), 2017
PMID: 28237193
Loss of chance associated with sub-optimal HPV vaccination coverage rate in France.
Uhart M, Adam M, Dahlab A, Bresse X., Papillomavirus Res 3(), 2017
PMID: 28720460
Vaccines are different: A systematic review of budget impact analyses of vaccines.
Loze PM, Nasciben LB, Sartori AMC, Itria A, Novaes HMD, de Soárez PC., Vaccine 35(21), 2017
PMID: 28427846
A systematic review of the health economic consequences of quadrivalent influenza vaccination.
de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, Pitman R, Wilschut JC, Postma MJ., Expert Rev Pharmacoecon Outcomes Res 17(3), 2017
PMID: 28613092
Cost-effectiveness of human papillomavirus vaccination in Germany.
Damm O, Horn J, Mikolajczyk RT, Kretzschmar MEE, Kaufmann AM, Deleré Y, Ultsch B, Wichmann O, Krämer A, Greiner W., Cost Eff Resour Alloc 15(), 2017
PMID: 28878573
Improving accountability in vaccine decision-making.
Timmis JK, Black S, Rappuoli R., Expert Rev Vaccines 16(11), 2017
PMID: 28929818
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
Boiron L, Joura E, Largeron N, Prager B, Uhart M., BMC Infect Dis 16(), 2016
PMID: 27084683
Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
Dolk C, Eichner M, Welte R, Anastassopoulou A, Van Bellinghen LA, Poulsen Nautrup B, Van Vlaenderen I, Schmidt-Ott R, Schwehm M, Postma M., Pharmacoeconomics 34(12), 2016
PMID: 27647004

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 26477039
PubMed | Europe PMC

Search this title in

Google Scholar